OTLK | Outlook Therapeutics Inc
Category: Consumer goods
Quick infos Trade prices Volume: Market Cap: 230.46M Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: Next ER: February 15, 2023
Earnings History Date EPS / Forecast Revenue / Forecast May 18, 2023 February 15, 2023 - / -0.0443- / -December 29, 2022 -0.06 / -0.067- / -August 18, 2022 - / -0.06- / -May 13, 2022 -0.09 / -0.06- / -view more
Historical Data Date Price Open High Low Vol Change ER May 27, 2022 1.690 1.550 1.700
1.538
495.44K 7.64% May 26, 2022 1.570 1.550 1.590
1.495
494.37K 4.67% May 25, 2022 1.500 1.500 1.520
1.460
564.39K 0% May 24, 2022 1.500 1.530 1.550
1.480
417.68K -4.46% May 23, 2022 1.570 1.570 1.600
1.536
566.58K 0% May 20, 2022 1.570 1.560 1.590
1.510
623.64K 3.29% May 19, 2022 1.520 1.500 1.540
1.490
640.98K -0.65% May 18, 2022 1.530 1.580 1.610
1.500
577.12K -6.13% May 17, 2022 1.630 1.610 1.638
1.555
479.89K 1.87% May 16, 2022 1.600 1.580 1.650
1.580
389.78K 0% view more
More profiles and info about the company News
Outlook enters definitive agreement for $31.8M convertible promissory note seekingalpha.com Dec 23, 2022 9:43 pm Outlook Therapeutics up 3% on $25M direct offering seekingalpha.com Dec 23, 2022 7:29 pm FDA accepts Outlook Therapeutics' biologics license application for wet AMD drug seekingalpha.com Oct 28, 2022 9:07 pm Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days marketwatch.com Aug 12, 2020 9:47 am
Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010 finance.yahoo.com Aug 12, 2020 8:00 am
Oncobiologics, Inc. (OTLK) May Report Negative Earnings: Know the Trend
Ahead of Q3 Release finance.yahoo.com Aug 6, 2020 12:32 am
Outlook Therapeutics Announces Closing of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules finance.yahoo.com Jul 17, 2020 8:05 am Outlook Therapeutics ties up with AmerisourceBergen for anticipated launch of wet AMD drug seekingalpha.com Sep 27, 2022 10:17 pm Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8% seekingalpha.com Aug 30, 2022 9:27 pm Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01 seekingalpha.com Aug 10, 2022 8:20 pm Outlook Therapeutics announces full cash pre-payment of convertible promissory note seekingalpha.com Jul 5, 2022 8:33 pm Outlook to re-submit application for eye disorder drug in Sept. after FDA correspondence seekingalpha.com Jun 14, 2022 8:45 pm Outlook stock slumps 38% as it pulls filing for eye disorder drug after FDA seeks more info seekingalpha.com May 31, 2022 8:38 pm Outlook Therapeutics GAAP EPS of -$0.09 misses by $0.03 seekingalpha.com May 13, 2022 8:06 pm Outlook Therapeutics Q1 2022 Earnings Preview seekingalpha.com May 13, 2022 12:20 am Outlook Therapeutics files for FDA approval of ONS-5010 for eye disorder seekingalpha.com Mar 31, 2022 9:14 pm Outlook Therapeutics GAAP EPS of -$0.08 seekingalpha.com Feb 14, 2022 9:12 pm Outlook Therapeutics provides business updates for 2022 seekingalpha.com Jan 25, 2022 9:37 pm Outlook Therapeutics EPS in-line seekingalpha.com Dec 22, 2021 9:22 pm Outlook Therapeutics tracks higher as CEO, COO buy shares seekingalpha.com Dec 8, 2021 5:20 am Talk about Outlook Therapeutics Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis
